Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients
详细信息 查看全文
- 作者：Eisuke Miyaki ; Michio Imamura ; Nobuhiko Hiraga ; Eisuke Murakami ; Tomokazu Kawaoka ; Masataka Tsuge ; Akira Hiramatsu ; Yoshiiku Kawakami ; Hiroshi Aikata ; C. Nelson Hayes and Kazuaki Chayama
- 刊名：Hepatology Research
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：46
- 期：8
- 页码：758-764
- 全文大小：478K
- ISSN：1872-034X
文摘
Although interferon (IFN)-free antiviral therapy is expected to improve the treatment response for chronic hepatitis C, the effect on liver function and liver fibrosis is unknown. In this study, we analyzed the long-term follow up of liver function parameters and liver fibrosis markers in genotype 1b hepatitis C virus (HCV)-infected patients treated with daclatasvir and asunaprevir.